Search

Your search keyword '"Aspergillus drug effects"' showing total 2,157 results

Search Constraints

Start Over You searched for: Descriptor "Aspergillus drug effects" Remove constraint Descriptor: "Aspergillus drug effects"
2,157 results on '"Aspergillus drug effects"'

Search Results

101. Suitability of starch/carvacrol nanofibers as biopreservatives for minimizing the fungal spoilage of bread.

102. Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor.

103. Novel naphthylamide derivatives as dual-target antifungal inhibitors: Design, synthesis and biological evaluation.

104. Studies on the efficacy of electrolysed oxidising water to control Aspergillus carbonarius and ochratoxin A contamination on grape.

105. Species distribution and antifungal susceptibility of Aspergillus clinical isolates in Lebanon.

106. Exploring the extremes: applying high concentration of yeast extract leads to drastic morphological changes and elimination of (+)-geodin and asterric acid production in Aspergillus terreus submerged cultures.

107. In Vitro Effects of Farnesol Alone and in Combination with Antifungal Drugs Against Aspergillus Clinical Isolates.

108. Reactive oxygen species altering the metabolite profile of the marine-derived fungus Dichotomomyces cejpii F31-1.

109. Comparison of electrolized water and multiple chemical sanitizer action against heat-resistant molds (HRM).

110. Antioxidant and antibacterial activities, interfacial and emulsifying properties of the apo and holo forms of purified camel and bovine α-lactalbumin.

111. Targeted potent antimicrobial benzochromene-based analogues: Synthesis, computational studies, and inhibitory effect against 14α-Demethylase and DNA Gyrase.

112. Antibacterial activity of the lichens Usnea Florida and Flavoparmelia caperata (Parmeliaceae).

113. Potent in vitro activity of curcumin and quercetin co-encapsulated in nanovesicles without hyaluronan against Aspergillus and Candida isolates.

114. The application of pharmaceutical quality by design concepts to evaluate the antioxidant and antimicrobial properties of a preservative system including desferrioxamine.

115. Aspergillus peritonitis in peritoneal dialysis patients: A systematic review.

116. Novel heterocyclic hybrids of pyrazole targeting dihydrofolate reductase: design, biological evaluation and in silico studies.

117. Rare/cryptic Aspergillus species infections and importance of antifungal susceptibility testing.

118. In vitro and in vivo antifungal activity of Cuminum cyminum essential oil against Aspergillus aculeatus causing bunch rot of postharvest grapes.

119. Multicentric Analysis of the Species Distribution and Antifungal Susceptibility of Cryptic Isolates from Aspergillus Section Fumigati .

120. Commercial green tea from Portugal: Comprehensive microbiologic analyses.

121. Development of active agents filled polylactic acid films for food packaging application.

122. Comparative Evaluation of MIRONAUT-AM and CLSI broth microdilution method for antifungal susceptibility testing of Aspergillus species against four commonly used antifungals.

123. How to interpret MICs of antifungal compounds according to the revised clinical breakpoints v. 10.0 European committee on antimicrobial susceptibility testing (EUCAST).

124. Cinnamyl Schiff bases: synthesis, cytotoxic effects and antifungal activity of clinical interest.

125. Antifungal and antimycotoxigenic metabolites from native plants of northwest Argentina: isolation, identification and potential for control of Aspergillus species.

126. Green and efficient biosynthesis of pectin-based copper nanoparticles and their antimicrobial activities.

127. Inhibitory effect of sweet whey fermented by Lactobacillus plantarum strains against fungal growth: A potential application as an antifungal agent.

128. Bacillus subtilis inhibits Aspergillus carbonarius by producing iturin A, which disturbs the transport, energy metabolism, and osmotic pressure of fungal cells as revealed by transcriptomics analysis.

129. Evaluating posaconazole dosing regimens of the different formulations against Aspergillus spp. in adults: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation.

130. New antimicrobial terpenoids and phloroglucinol glucosides from Syzygium szemaoense.

131. Toxicity of three rare earth elements, and their combinations to algae, microcrustaceans, and fungi.

132. Effect of rhamnolipid on the physicochemical properties and interaction of bacteria and fungi.

133. Phytochemical, antimicrobial and time-kill kinetics potentials of Euphorbia nivulia Buch.-Ham.: A Cholistan desert medicinal plant.

134. Efficacy of volatile compounds from Streptomyces philanthi RL-1-178 as a biofumigant for controlling growth and aflatoxin production of the two aflatoxin-producing fungi on stored soybean seeds.

135. Design, synthesis ADMET and molecular docking of new imidazo[4,5-b]pyridine-5-thione derivatives as potential tyrosyl-tRNA synthetase inhibitors.

136. Antifungal activity of Bignoniaceae plants on Aspergillus carbonarius and Aspergillus niger .

137. Molecular identification, phylogenetic analysis and antifungal susceptibility patterns of Aspergillusnidulans complex and Aspergillusterreus complex isolated from clinical specimens.

138. Improvement of the pharmacokinetic/pharmacodynamic relationship in the treatment of invasive aspergillosis with voriconazole. Reduced drug toxicity through novel rapid release formulations.

139. In vitro susceptibility of Aspergillus and Fusarium associated with equine keratitis to new antifungal drugs.

140. Efficacy of nanoparticle encapsulation on suppressing oxidation and enhancing antifungal activity of cyclic lipopeptides produced by Bacillus subtilis.

141. Efficacy of sodium hypochlorite and peracetic acid against Aspergillus nomius in Brazil nuts.

142. 3-Methylxanthine production through biodegradation of theobromine by Aspergillus sydowii PT-2.

143. Protective Activity of Programmed Cell Death Protein 1 Blockade and Synergy With Caspofungin in a Murine Invasive Pulmonary Aspergillosis Model.

144. Isavuconazole Treatment of Cerebral and Pulmonary Aspergillosis in a Pediatric Patient With Acute Lymphoblastic Leukemia: Case Report and Review of Literature.

145. Antifungal susceptibility testing in Candida, Aspergillus and Cryptococcus infections: are the MICs useful for clinicians?

146. GC-MS analysis, antimicrobial, antioxidant, antilipoxygenase and cytotoxic activities of Jacaranda mimosifolia methanol leaf extracts and fractions.

147. Critical thresholds of 1-Octen-3-ol shape inter-species Aspergillus interactions modulating the growth and secondary metabolism.

148. Facile, one-pot biosynthesis and characterization of iron, copper and silver nanoparticles using Syzygium cumini leaf extract: As an effective antimicrobial and aflatoxin B1 adsorption agents.

149. Ibrexafungerp: A novel oral glucan synthase inhibitor.

150. Utility of systemic voriconazole in equine keratomycosis based on pharmacokinetic-pharmacodynamic analysis of tear fluid following oral administration.

Catalog

Books, media, physical & digital resources